Regulus Therapeutics (NASDAQ:RGLS) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Regulus Therapeutics (NASDAQ:RGLSFree Report) in a research note released on Monday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Regulus Therapeutics Price Performance

Shares of NASDAQ:RGLS opened at $1.65 on Monday. Regulus Therapeutics has a 1 year low of $0.76 and a 1 year high of $2.14. The company has a market cap of $33.36 million, a PE ratio of -1.04 and a beta of 1.47. The stock’s 50-day moving average is $1.31 and its 200 day moving average is $1.36.

Institutional Trading of Regulus Therapeutics

A number of hedge funds have recently made changes to their positions in RGLS. Vanguard Group Inc. boosted its position in shares of Regulus Therapeutics by 21.4% in the 1st quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock worth $1,096,000 after purchasing an additional 648,121 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Regulus Therapeutics in the 1st quarter worth approximately $8,656,000. Northern Trust Corp boosted its position in shares of Regulus Therapeutics by 42.9% in the 1st quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 50,518 shares in the last quarter. Renaissance Technologies LLC lifted its position in Regulus Therapeutics by 498.2% in the 1st quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 111,100 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in Regulus Therapeutics in the 3rd quarter valued at approximately $54,000. 62.22% of the stock is owned by institutional investors.

About Regulus Therapeutics

(Get Free Report)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

Further Reading

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.